This clinical trial is focused on studying a liver condition known as Metabolic Dysfunction-Associated Steatohepatitis (MASH), which can lead to a type of liver scarring called compensated cirrhosis. The study will evaluate a treatment called efinopegdutide, also known by its code name MK-6024. This treatment is administered as a solution for injection using a pre-filled syringe. The purpose of the study is to assess the effect of efinopegdutide on reducing liver fat content and to evaluate its safety and tolerability.

Participants in the study will receive either efinopegdutide or a placebo, which is a substance with no active medication. The study will last for 28 weeks, during which the changes in liver fat content will be monitored. The study will also track any side effects experienced by participants and whether any participants discontinue the treatment due to these effects. The goal is to understand how efinopegdutide affects liver health and its safety for patients with MASH.

Throughout the study, various health indicators will be measured, including changes in liver stiffness and body weight. These measurements will help researchers determine the overall impact of efinopegdutide on liver health. The study aims to provide valuable insights into the potential benefits and risks of using efinopegdutide for treating MASH-related liver conditions.